Alerdin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alerdin

Property Description
Active ingredient Desloratadine
Form Tablet, Oral solution, Syrup
Pharmacological class Second-generation antihistamine, Selective H1-receptor antagonist
Common use Relief of common allergic symptoms
Origin Synthetic

What Type of Medicine is Alerdin?

Alerdin is a medicinal compound defined by its active ingredient, Desloratadine, which is classified as a second-generation antihistamine. The drug functions as a selective peripheral H1-receptor antagonist, acting on specific sites outside the central nervous system. This molecular property is the basis for its non-sedating profile, a key feature that minimizes the risk of drowsiness commonly associated with older compounds. Desloratadine is the principal active metabolite of loratadine, possessing a high degree of potency and providing a sustained, long-acting therapeutic effect. Pharmacological studies have consistently supported this classification and its long duration of action.

Composition, Origin, and Available Forms

The therapeutic effect of Alerdin is provided solely by the synthetic chemical compound Desloratadine, classifying it as a single product formulation. This substance is prepared for oral administration alongside standard pharmaceutical excipients. Desloratadine preparations are widely utilized in allergic management across various markets. The liquid and solid preparations, which include the tablet, syrup, and oral solution, ensure suitable administration for various patient groups, often including children over six months (depending on local regulations).

Alerdin's General Purpose

The general purpose of Alerdin is to control and relieve the uncomfortable symptoms that arise from allergic responses by preventing the actions of histamine. Clinical experience has long recognized the efficacy of H1-receptor antagonists for this purpose. The drug achieves this by effectively blocking the H1-receptor, interrupting the body’s allergic cascade. This highly selective action provides relief from common allergic symptoms, such as sneezing, nasal discharge, itching, and the appearance of hives (urticaria), facilitating the management of conditions like seasonal allergic rhinitis.

What side effects are possible with Alerdin?

The official safety profile for Alerdin (desloratadine) outlines documented adverse reactions organized by frequency and affected body systems, as established by governmental regulatory agencies.

Frequency-Classified Adverse Reactions

Adverse reactions reported in clinical trials for adults and adolescents (12 years) more frequently than placebo are classified as Common.

Classification Representative Adverse Reactions
Common (Reported in 1/100 patients) Fatigue, Dry mouth, Headache
Very Rare / Not Known Dizziness, Somnolence, Insomnia, Tachycardia, Palpitations, Nausea, Vomiting, Diarrhea, Myalgia, Hypersensitivity reactions

System-Organ Classes and Serious Reactions

The documented effects span several regulatory categories, including Nervous System Disorders (e.g., headache, seizures), Gastrointestinal Disorders (e.g., dry mouth, vomiting), Cardiac Disorders (e.g., tachycardia, palpitations), and Hepatobiliary Disorders (e.g., hepatitis, elevated liver enzymes).

Serious Adverse Reactions explicitly listed in official product information include severe Hypersensitivity Reactions such as anaphylaxis and angioedema, along with Hepatitis and post-marketing reports of Seizures.

Population-Specific Safety Considerations

The official labeling includes safety notes for specific populations. Use requires caution in patients with a medical or familial history of seizures. Caution is also advised in cases of severe renal impairment and hepatic impairment due to altered drug clearance. Furthermore, the use of desloratadine is generally not recommended during breastfeeding as the substance is known to be excreted into breast milk.

Overdose and Emergency Response

The official regulatory documentation for Alerdin (Desloratadine) defines the overdose profile primarily as an exaggeration of the known adverse effects. The most frequently documented clinical manifestation in controlled studies involving high exposures is increased somnolence (drowsiness). However, post-marketing surveillance reports have also noted the potential for more severe outcomes, including effects on the cardiovascular system such as arrhythmia and QT prolongation, as well as neurological effects like seizures.


When to Seek Immediate Medical Help

Regulatory guidance emphasizes that immediate medical help is required if severe manifestations are present. Life-threatening signs that necessitate contacting emergency services (e.g., 911) or the poison control helpline include collapse, having a seizure, or experiencing trouble breathing.

The documented management for Alerdin overdosage is limited to symptomatic and supportive treatment. Official prescribing information states that procedures to remove unabsorbed active substance should be considered. Regulatory documents confirm that no specific antidote is known, and the drug is not eliminated by haemodialysis. A specific note addresses the paediatric population, indicating that the magnitude of adverse effects may be higher in children compared to adults.

Therapeutic Uses of Alerdin

Alerdin is primarily used to provide symptomatic support across two major therapeutic domains, aligning with official therapeutic areas of use. Its core benefit helps ease the overall symptom burden that may interfere with daily functioning and comfort.

Management of Allergic Rhinitis (Seasonal and Perennial)

Therapeutic uses include managing the symptoms of allergic rhinitis (both seasonal and perennial). The medication may assist with the symptom clusters associated with conditions presenting with systemic discomfort, such as frequent sneezing, clear runny nose, itchy/watery eyes, and pronounced pruritus. It helps maintain a sense of stability and comfort during episodes of heightened symptoms.


Relief from Chronic Urticaria (Hives) and Intense Itching

Alerdin is also relevant for easing the symptoms of Chronic Idiopathic Urticaria (hives), a condition involving episodic or fluctuating manifestations. This application targets the intense pruritus (itching) and assists with the reduction of visible wheals (raised welts) that affect functional stability. It contributes to improved comfort and supports general well-being during symptomatic phases.


Quick Fact: Therapeutic Focus: Easing Itching and Hives Manifestations

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Alerdin, which contains the active ingredient cetirizine, is generally suitable for use by most adults and children, depending on the dosage form and age. However, certain conditions and circumstances require caution or make its use inadvisable.

Contraindications and Precautions

Consult a healthcare professional before taking Alerdin, particularly if you have or are experiencing any of the following:

Do Not Use If Use With Caution If
Allergy: Known hypersensitivity to cetirizine, hydroxyzine, or any piperazine derivatives. Kidney or Liver Impairment: Dosage adjustment is often required, especially for severe kidney disease.
Severe Renal Impairment: Use is generally contraindicated. Epilepsy/Seizures: Caution is advised, as antihistamines may rarely increase the risk of seizures.

Special Populations

  • Pregnancy and Breastfeeding: Use during pregnancy is generally recommended only if clearly necessary, as limited data is available. Cetirizine passes into breast milk and is not typically recommended for use while breastfeeding. Always consult your doctor.
  • Children: The appropriate use and dosage for children vary by age and formulation; consult the product label or a healthcare provider for guidance on pediatric dosing.
  • Older Adults: Older patients may be more susceptible to side effects, particularly drowsiness, and may require a lower dose, especially if they have kidney or liver issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alerdin has a documented interaction profile primarily focused on pharmacodynamic effects, though specific pharmacokinetic studies have also been performed.

Documented Interactions

Interaction Type Interacting Products or Categories Clinical Implication / Constraint
Additive CNS Effects Central Nervous System (CNS) depressants, including alcohol, tranquilizers, and other sedating antihistamines. Caution is advised due to the potential for increased drowsiness and intensified CNS depression. Post-marketing reports of alcohol intolerance have been noted.
Anticholinergic Effects Other antihistamines and specific anticholinergic agents (e.g., Atropine, Scopolamine). Co-administration may intensify effects such as dry mouth or difficulty with urination.
Metabolic Pathway Specific P450 enzyme inhibitors (e.g., Erythromycin, Ketoconazole). Clinical studies did not find a clinically relevant pharmacokinetic interaction requiring dose adjustment.

Official Constraints

The regulatory labeling advises caution with the concurrent use of alcohol and other CNS depressants due to the potential for additive effects. Although the medicine does not appear to have clinically significant pharmacokinetic interactions with certain strong inhibitors, the pharmacodynamic risks associated with combining it with substances that affect central nervous system function remain a key consideration. Interaction studies in the pediatric population have not been performed according to regulatory documents.

Mechanism of Action

Alerdin functions primarily as an inverse agonist targeting the histamine H1 receptor. Its molecular mechanism involves binding to the receptor and stabilizing it in an inactive conformation. This action competitively prevents the binding of endogenous histamine—a key mediator released from mast cells—to the receptor site. By blocking this interaction, Alerdin interrupts the typical H1-mediated signaling cascade.

This molecular blockade modulates the intracellular pathway by inhibiting the subsequent activation of coupled G q/ 11 proteins. Histamine binding normally triggers these proteins, leading to the hydrolysis of phosphatidylinositol-4,5-bisphosphate ( PIP2) into inositol triphosphate ( IP3) and diacylglycerol ( DAG). Alerdin prevents this initial signal transduction step, thereby blocking the downstream cellular processes.

The system-level physiological consequence of this H1 receptor antagonism is the modulation of microvasculature permeability and smooth muscle activity. By maintaining cellular homeostasis and limiting histamine's effects on vascular tone, Alerdin restricts the resultant physiological responses associated with H1 activation.

Dosage and Administration Information

Standard Dosing and Administration Route

Alerdin is administered exclusively via the oral route across all its approved formulations, which include standard tablets, the oral solution or syrup, and orally disintegrating tablets (ODT). The established dose for adults and adolescents 12 years and older is 5 mg taken once daily. This once-daily frequency is consistent with the drug’s long duration of action and is the maximum recommended regimen.

Administration Context and Form-Specific Handling

The medication may be administered without regard to meals, offering flexibility in daily intake. Due to differences in formulation, precise handling procedures are required. The oral solution must be measured using a calibrated dosing device to ensure accurate dose delivery, a procedural constraint particularly relevant for pediatric administration. In contrast, the ODT formulation requires specific handling with dry hands and immediate consumption upon removal from its blister packaging.

Population Adjustments and Treatment Patterns

Official usage guidelines include required modifications for certain patient populations. For adults with known hepatic or renal impairment, the recommended starting frequency is modified to 5 mg every other day to mitigate the risk of increased systemic exposure. Treatment duration is not fixed; use may be intermittent for seasonal conditions or continuous for the management of chronic conditions such as perennial allergic rhinitis, dictated by symptom persistence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alerdin

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The research base for Alerdin was established primarily through short-term Randomized Controlled Trials (RCTs). These are studies used in research exploring how symptoms change over time. Participants, including adults and adolescents, were observed over defined time intervals, with Alerdin often compared against a placebo. Studies examined conditions characterized by fluctuating or episodic manifestations, such as seasonal allergies.

Studies focused on outcomes related to physical discomfort. Researchers primarily measured changes in Total Symptom Scores (TSS), which combine the measurement of several individual symptoms, including sneezing, runny nose, and itching of the eyes or nose. Research highlights changes measured in symptom scores during the study period. Additionally, research explored short-term symptom changes concerning outcomes reflecting daily functioning or activity level, such as the impact on sleep and overall Quality of Life, which are patient-reported outcomes describing perceived discomfort.


Evidence for Use in Chronic Urticaria (Hives)

For chronic urticaria, or hives, the research base consists of short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, examining symptom intensity or variability in adult and adolescent populations. Alerdin was evaluated in conditions involving periods of heightened symptoms.

Clinical findings describe patterns related to changes in the Urticaria Activity Score (UAS), which monitors the severity of pruritus (itching) and the number and size of wheals (hives). Studies also reported how symptoms evolved in the observed populations, and research provides insight into short-term changes. In some cases, studies explored the use of amounts exceeding the standard dose, and studies monitored responses over defined time intervals.


Duration of Study and Long-Term Follow-up

The follow-up durations for the primary efficacy studies are limited. The most detailed controlled research was primarily conducted for short periods, generally between two and six weeks.

Evidence related to long-term monitoring of symptoms and daily-life functioning over many months is limited to observational settings and post-marketing surveillance reports. These reports evaluate daily-life functioning and contribute to the broader evidence landscape. However, results for outcomes past the few weeks studied in the initial trials rely on less controlled methods.


Gaps in Research and Areas of Uncertainty

The research landscape includes several limitations documented in official literature. Follow-up durations were limited in the gold-standard RCTs, restricting the insight into long-term outcomes for patients who may use Alerdin over many months. Comparative evidence is lacking, particularly regarding direct, head-to-head trials against all other similar second-generation antihistamines. Data for certain groups remain insufficient, especially concerning specific subgroups of the elderly population or those with complex comorbidities.

Frequently Asked Questions (FAQ)

Common questions about Alerdin (FAQ)


Q: How long does it usually take to notice the effects of Alerdin?

A: Official information on the drug’s pharmacokinetics indicates that the time to reach maximum concentration in the blood, which is a key marker for absorption, is generally around three hours after administration. This pharmacokinetic data describes the time until the highest concentration is reached.

Q: Is Alerdin appropriate for use by older adults?

A: According to official prescribing information, no specific dosage adjustment is recommended for older adults, generally defined as individuals 65 years and older. While the body may process the medicine slightly differently in this age group, official documents indicate that a standard regimen is typically maintained.

Q: Do I need a prescription to get Alerdin?

A: The regulatory classification of this medicine, determining if a prescription is required, can vary significantly depending on the country. It may be available as an over-the-counter medicine in certain doses or formulations, while others require a prescription. The local availability and required classification will determine access.

Q: What types of side effects are most commonly reported with Alerdin?

A: Official clinical trial data describes the most commonly reported side effects as typically including headache, dry mouth, and feelings of tiredness or sleepiness. The full list of potential side effects is available for review in the official product information.

Q: Why is Alerdin sometimes described as 'non-drowsy'?

A: The drug is often noted in labeling as causing less sedation compared to older medications in its class. However, official warnings describe the need for caution because side effects like drowsiness or dizziness can still be experienced by some patients.

Q: Is it normal to feel a minor headache after starting Alerdin?

A: Headache is listed as one of the most common adverse events reported in clinical data and official product information. Official product information notes this frequency, meaning a minor headache is among the commonly reported occurrences.

Q: How long does Alerdin stay in the body after the last use?

A: The official pharmacokinetic data describes the medicine as having a long half-life, which is the time it takes for half the drug to be eliminated from the body. For this drug, the mean plasma elimination half-life is reported to be approximately 27 hours.

Q: Are there any known interactions between Alerdin and certain foods?

A: Studies found that taking this medicine with food, or even with specific agents like grapefruit juice, did not have a clinically relevant effect on how the drug is absorbed. The official guidance states that it can be taken without regard to meals.

Q: What happens if I forget to use Alerdin?

A: Official patient instructions typically advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance states that the missed dose should be skipped, and the regular schedule resumed without doubling the amount.

Q: Is Alerdin suitable for people who have certain pre-existing conditions?

A: Official documentation provides warnings for use in individuals with pre-existing health conditions such as epilepsy due to a potential risk of seizure aggravation. Furthermore, official documents indicate specific modifications or contraindications are necessary for those with kidney disease.

Q: Can Alerdin affect my ability to drive or operate machinery?

A: Regulatory warnings state that the medicine can cause side effects like drowsiness or dizziness. Because of this potential impact on mental alertness, official guidance indicates caution is necessary when engaging in activities that require concentration, such as driving or operating heavy machinery.

Q: Does Alerdin interact with alcohol?

A: Official labeling includes a specific warning regarding the use of alcohol while taking this medicine. This is because combining the two may increase the risk of sedation and central nervous system (CNS) effects.

Q: Why are there different strengths or formulations of Alerdin mentioned online?

A: According to official regulatory documents detailing dosage forms, the medicine is manufactured and approved in multiple strengths and forms, including standard tablets and liquid solutions. These different options are designed to accommodate various patient populations, particularly children.

Q: Can Alerdin be crushed or split if the pill is too large?

A: Official regulatory guidelines provide specific handling instructions for special forms like orally disintegrating tablets, but typically do not advise crushing or splitting standard tablets unless they are officially scored. Official guidance suggests standard tablets should be swallowed whole to ensure proper drug delivery.

Q: What are the major contraindications listed for Alerdin?

A: The drug is formally contraindicated for individuals who have a known allergy or hypersensitivity to the active ingredient or its related compounds. It is also contraindicated for patients diagnosed with severe renal (kidney) impairment.

Q: Is Alerdin known by any other name internationally?

A: Yes, drugs are frequently marketed internationally under different brand names. The active ingredient in this drug is known by a single generic name and multiple brand names globally.

Q: Does taking Alerdin at a certain time of day matter?

A: While the drug can generally be taken at any time of day, some official sources indicate a preference for evening administration. This preference is noted because of the potential for minor drowsiness, which is often considered more manageable when taken before sleep.

Q: Is Alerdin safe for use during pregnancy, according to official documents?

A: Official guidance on use during pregnancy requires that a healthcare professional be consulted first. The regulatory guidance requires clinical consideration of whether the potential benefit outweighs the potential risks to the developing fetus.

Q: Why do some people say Alerdin made them feel energized?

A: Official reports of adverse events include rare instances of what is referred to as a paradoxical reaction. This can involve effects such as agitation, restlessness, and feelings of increased energy.

Q: Are there any known drug-disease interactions for Alerdin?

A: Regulatory documents list specific disease-related interactions, and official documents describe specific recommendations or contraindications for individuals with certain health issues. This includes those with a history of epilepsy and those with impaired kidney function.

Q: What does official guidance say about using Alerdin while breastfeeding?

A: Official guidance requires consultation with a healthcare professional before using this medicine while breastfeeding. The active ingredient may pass into breast milk, and official guidance states the risks and benefits must be assessed by a clinician.

Q: How long can I expect the relief from Alerdin to last?

A: The drug's long half-life contributes to its duration of action, which is generally described in official documents as providing relief that lasts up to 24 hours. This supports the standard once-daily dosing regimen.

Q: Is there a generic version of Alerdin available?

A: Yes, the active ingredient of this brand-name medicine is available in generic form. These generic versions are approved by regulatory bodies such as the FDA and Health Canada, subject to national availability.

Q: Are there any known weight-related side effects with Alerdin?

A: Official reports of adverse events list effects related to metabolism and nutrition. These include changes in appetite, with reported instances of both increased appetite and decreased appetite.

Q: What are the major warnings mentioned in the official prescribing information for Alerdin?

A: Major warnings in the official prescribing information relate to the potential for central nervous system effects, such as drowsiness and dizziness. Warnings also indicate the need for caution for patients with existing kidney problems or a history of epilepsy.

Q: Does Alerdin cause any changes in appetite?

A: Official reports of adverse events list effects on metabolism and nutrition. These changes in appetite include both instances of increased appetite and decreased appetite.

Q: Is Alerdin considered habit-forming or addictive?

A: Official regulatory documentation describes this medicine as having no known potential for abuse or habit formation. It is not classified as a controlled substance under relevant drug regulations.

Q: Is Alerdin recommended for use in children under a certain age?

A: Official regulatory guidance on the use of this medicine in the pediatric population generally describes that use is not recommended for children and infants under the age of four.

Q: What is the active ingredient in Alerdin?

A: The medicine is a brand-name drug whose active pharmaceutical ingredient is Cetirizine. Regulatory documents identify this ingredient as responsible for the drug’s intended effects.

Q: Are there specific patient characteristics that make Alerdin less suitable?

A: Official documentation specifies certain patient characteristics that make the drug less suitable or formally contraindicated. These include known hypersensitivity to the drug or related compounds, and the presence of severe renal (kidney) impairment.

Q: What official documents describe Alerdin’s purpose?

A: The approved purpose, uses, and conditions for this medicine are formally described and regulated by national drug authorities. These details are found in official documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Q: Is it possible to be allergic to Alerdin?

A: Yes, the medicine is formally contraindicated for individuals with a known hypersensitivity (allergy) to the active ingredient or related compounds. Official reports also list hypersensitivity reactions as potential adverse events.

How should Alerdin be stored and disposed of?

How to Store and Dispose of Alerdin?

Official regulatory guidance outlines specific requirements for storing and disposing of Alerdin (Desloratadine) to maintain product stability and ensure household safety.

Storage Requirements

Storage Factor Official Instruction
Temperature Do not store above 30 C and keep from freezing.
Packaging Store in the original package and keep the container tightly closed to protect it from moisture.
Protection Store in the original package in order to protect the product from light and moisture.

Child Safety and Disposal

The product must be kept out of the sight and reach of children as a mandatory safety precaution. For disposal, unused or expired Alerdin should not be thrown away via wastewater or household trash if local collection programs are available. Official instructions vary; some regulations indicate no special requirements, while others advise avoiding release of the active ingredient to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alerdin found in:

A-Z Index: